دورية أكاديمية
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
| العنوان: | Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort. |
|---|---|
| المؤلفون: | Van Muijen ME; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, NL-6500 HB Nijmegen, The Netherlands. marloes.vanmuijen@radboudumc.nl., Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, Dodemont SRP, Kop EN, Berends MAM, Koetsier MIA, Mommers JM, Körver JEM, Tupker RA, De Bruin-Weller MS, Weppner-Parren LJMT, Peters B, Kleinpenning MM, Kuijpers ALA, Arnold WP, Van Lümig PPM, Van den Reek JMPA, De Jong EMGJ |
| المصدر: | Acta dermato-venereologica [Acta Derm Venereol] 2022 May 16; Vol. 102, pp. adv00712. Date of Electronic Publication: 2022 May 16. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: MJS Publishing Country of Publication: Sweden NLM ID: 0370310 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-2057 (Electronic) Linking ISSN: 00015555 NLM ISO Abbreviation: Acta Derm Venereol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : Uppsala, Sweden : MJS Publishing Original Publication: Stockholm : Acta dermato-venereologica |
| مواضيع طبية MeSH: | Biological Products*/adverse effects , Psoriasis*/diagnosis , Psoriasis*/drug therapy, Adalimumab/therapeutic use ; Cohort Studies ; Etanercept/therapeutic use ; Humans ; Immunologic Factors ; Prospective Studies ; Severity of Illness Index ; Treatment Outcome ; Ustekinumab/therapeutic use |
| مستخلص: | Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study. |
| References: | Br J Dermatol. 2018 Feb;178(2):509-519. (PMID: 29094341) J Eur Acad Dermatol Venereol. 2019 Mar;33(3):553-559. (PMID: 30317679) J Am Acad Dermatol. 2013 Jan;68(1):57-63. (PMID: 22846689) J Am Acad Dermatol. 2021 Oct;85(4):1028-1030. (PMID: 33762130) Br J Dermatol. 2017 Apr;176(4):1001-1009. (PMID: 27579864) Dermatology. 2022;238(4):615-619. (PMID: 34775387) Int J Dermatol. 2022 Mar;61(3):e107-e108. (PMID: 33945151) Dermatol Ther. 2020 May;33(3):e13313. (PMID: 32181962) Br J Dermatol. 2020 May;182(5):1158-1166. (PMID: 31286471) J Dermatol Sci. 2020 Jul;99(1):53-61. (PMID: 32600737) J Dermatol. 2020 Apr;47(4):405-408. (PMID: 31994229) PLoS One. 2019 Aug 14;14(8):e0220868. (PMID: 31412060) J Immunol Res. 2019 Sep 10;2019:2546161. (PMID: 31583255) Acta Derm Venereol. 2021 Oct 26;101(10):adv00579. (PMID: 34642768) Dermatol Ther. 2022 Jan;35(1):e15166. (PMID: 34676662) J Dermatolog Treat. 2018 Aug;29(5):481-486. (PMID: 29058948) J Dermatolog Treat. 2019 Feb;30(1):19-26. (PMID: 29726739) Eval Health Prof. 2009 Sep;32(3):207-28. (PMID: 19679634) Arch Dermatol. 2012 Apr;148(4):463-70. (PMID: 22508869) Dermatol Ther. 2020 Nov;33(6):e14066. (PMID: 32713119) Br J Dermatol. 2017 Oct;177(4):1033-1042. (PMID: 28580579) J Am Acad Dermatol. 2016 May;74(5):851-61.e4. (PMID: 26853180) J Dermatolog Treat. 2020 Aug;31(5):476-483. (PMID: 31557063) J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3. (PMID: 29969700) J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317. (PMID: 28240404) J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. (PMID: 29438757) Dermatol Ther. 2021 Jan;34(1):e14673. (PMID: 33314658) Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. (PMID: 31917873) J Dtsch Dermatol Ges. 2021 Jan;19(1):47-56. (PMID: 33377312) JAMA Dermatol. 2021 Jan 1;157(1):66-73. (PMID: 33263718) Expert Opin Biol Ther. 2021 Sep;21(9):1299-1310. (PMID: 34114515) J Invest Dermatol. 2017 Aug;137(8):1646-1654. (PMID: 28457908) |
| المشرفين على المادة: | 0 (Biological Products) 0 (Immunologic Factors) FU77B4U5Z0 (Ustekinumab) FYS6T7F842 (Adalimumab) OP401G7OJC (Etanercept) |
| تواريخ الأحداث: | Date Created: 20220331 Date Completed: 20220518 Latest Revision: 20221021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9574692 |
| DOI: | 10.2340/actadv.v102.206 |
| PMID: | 35356990 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1651-2057 |
|---|---|
| DOI: | 10.2340/actadv.v102.206 |